Recognition of Philadelphia chromosome‐like acute lymphoblastic leukemia as part of routine diagnostic work‐up

Introduction Philadelphia chromosome (Ph)‐like acute lymphoblastic leukemia (ALL) is a biologically and clinically challenging subtype of B‐cell ALL which has been incorporated into the 2016 revision of the World Health classification of acute leukemia. It is independently associated with poor outcome. As it can only be reliably detected by expression profiling, it is difficult to diagnose with routine methods. Its recognition has become of greater importance due to prognostication and even more due to the new diagnostic options given by targeted therapies. There is still no standardized diagnostic test enabling its prompt recognition. Here, we introduce our approach how to detect it by combination of widely available techniques. Methods 179 ALL patients diagnosed in our center during the last 8 years were included. Data on immunophenotype and cytogenetics were used to select patients with potentially Ph‐like ALL (65/179). CRLF2 gene rearrangement (CRLF2‐r) was tested by FISH in 59/65 patients, and next‐generation sequencing was done by Archer FusionPlex ALL kit in 34 patients. TSLPR expression was determined in 20 patients. Results Philadelphia chromosome‐like aberrations were confirmed in 9 patients. In 10% of tested samples, CRLF2‐r was confirmed. Due to a lack of material, NGS was done only in a half of potentially Ph‐like cases. In 10%, other Ph‐like fusions were found by NGS. Conclusions The obtained frequencies, and genetic and patients' characteristics are in concordance with the literature data, ensuring a reliable detection of this challenging ALL subtype. The proposed algorithm allows detection of Ph‐like ALL at reasonable cost and acceptable workload.